Combining cellular immunotherapy was an optional choice for unresectable advanced HCC: A systematic review and meta-analysis - 16/01/21
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
| pagine | 12 |
| Iconografia | 4 |
| Video | 0 |
| Altro | 0 |
Highlights |
• | Our meta-analysis showed combining cellular immunotherapy in advanced HCC could increase the complete response rate, and thereafter extend the progression-free and overall survival rate. |
• | Subgroup analysis suggested that combining use of CIK and DC or using CIK alone could provide the benefit in survival outcome. |
Summary |
Background |
The efficacy of cellular immunotherapy in advanced hepatocellular carcinoma (HCC) was controversial. This study was conducted to compare the effectiveness of combining cellular immunotherapy with that of incurable treatment alone.
Methods |
The Ovid Medline, Embase, Cochrane Library and Pubmed were systematically searched due to January 8th 2020. The keywords include “immunotherapy”, “HCC” and study type. Treatment response was evaluated and progression-free survival (PFS) and overall survival (OS) were calculated using hazard ratio (HR) and 95% confidence interval (CI).
Results |
A total of 19 studies with 1275 patients were included in the meta-analysis. The median complete response rate (CR) was 19% in combining cellular immunotherapy comparing to 9% in the control group (RR=0.55, P=0.003). No significant difference was found in partial response and stable disease (RR=1.06 and 0.78, P>0.05, respectively). The progression disease rate was higher in the non-cellular immunotherapy group (31%) compared to the cellular immunotherapy group (RR=2.20, P=0.002). Patients treating with cellular immunotherapy had a better OS and PFS compared to those without cellular immunotherapy (HR=0.52 and 0.63, P<0.001). In the subgroup analysis, the only CIK infusion therapy and combined DC with CIK perfusion therapy patients had a better OS (HR=0.52 and 0.49, P<0.001 and P=0.002, respectively).
Conclusion |
Our results suggested that combining use of cellular immunotherapy in advanced HCC could increase the complete response rate, and thereafter extend the progression-free and overall survival rate. Subgroup analysis suggested that combining use of CIK and DC or using CIK alone could provide the benefit in survival outcome.
Il testo completo di questo articolo è disponibile in PDF.Keywords : Hepatocellular carcinoma, Immunotherapy, Advanced, Survival
Abbreviations : hepatocellular carcinoma, transarterial chemoembolization, radiofrequency ablation, cytokine-induced killer cells, dendritic cells, preferred reporting items for systematic review and meta-analysis, randomized control trials, natural killer cells, American Joint Committee on Cancer, Barcelona Clinic Liver Cancer, overall response rate, disease control rate, complete response, partial response, stable disease, progression disease, progression-free survival, overall survival, Response Evaluation Criteria in Solid Tumors, Newcastle-Ottawa Quality Assessment Scale, relative risk, hazard ratio, confidence intervals
Mappa
Vol 45 - N° 1
Articolo 101440- gennaio 2021 Ritorno al numero
Articolo precedente
- Absence of impact of direct acting antivirals for hepatitis C virus on recurrent hepatocellular carcinoma tumor growth in the AFEF/ANRS CO22 Hepather cohort
- Anais Vallet-Pichard, Jean-Michel Correas, Celine Dorival, Fabien Zoulim, Albert Tran, Marc Bourlière, Paul Calès, Dominique Guyader, Jean-Pierre Bronowicki, Dominique Larrey, Christophe Hezode, Veronique Loustaud-Ratti, Jerome Gournay, Victor de Ledinghen, Tarik Asselah, Nathalie Ganne, Sophie Metivier, Olivier Chazouillères, Vincent Leroy, Isabelle Rosa, Didier Samuel, Philippe Mathurin, Carole Cagnot, Helene Fontaine, Fabrice Carrat, Stanislas Pol, AFEF ANRS study group, Delphine Bonnet, Virginie Payssan-Sicart, Chloe Pomes, François Bailly, Marjolaine Beaudoin, Dominique Giboz, Kerstin Hartig-Lavie, Marianne Maynard, Eric Billaud, David Boutoille, Morane Cavellec, Marjorie Cheraud-Carpentier, Isabelle Hubert, Jaouad Benhida, Adrien Lannes, Françoise Lunel, Frédéric Oberti, Nathalie Boyer, Nathalie Giuily, Corinne Castelnau, Giovanna Scoazec, Aziza Chibah, Sylvie Keser, Karim Bonardi, Anaïs Vallet-Pichard, Philippe Sogni, Juliette Foucher, Jean-Baptiste Hiriart, Amy Wilson, Sarah Shili, Faiza Chermak, Christelle Ansaldi, Nisserine Ben Amara, Laëtitia Chouquet, Emilie De Luca, Valérie Oules, Rodolphe Anty, Eve Gelsi, Régine Truchi, Elena Luckina, Nadia Messaoudi, Joseph Moussali, Barbara De Dieuleveult, Damien Labarriere, Pascal Poter, Si Nafa Si Ahmed, Véronique Grando-Lemaire, Pierre Nahon, Valérie Bourcier, Séverine Brulé, Thomas Stalhberger, Caroline Jezequel, Audrey Brener, Anne Laligant, Aline Rabot, Isabelle Renard, Thomas F. Baumert, Michel Dofföel, Catherine Mutter, Pauline Simo-Noumbissie, Esma Razi, Hélène Barraud, Mouni Bensenane, Abdelbasset Nani, Sarah Hassani-Nani, Marie-Albertine Bernard, Georges-Philippe Pageaux, Michael Bismuth, Ludovic Caillo, Stéphanie Faure, Marie-Pierre Ripault, Christophe Bureau, Jean Marie Peron, Marie-Angèle Robic, Léa Tarallo, Marine Faure, Bruno Froissart, Marie-Noelle Hilleret, Jean-Pierre Zarski, Odile Goria, Victorien Grard, Hélène Montialoux, Muriel François, Christian Ouedraogo, Christelle Pauleau, Anne Varault, Tony Andreani, Bénédicte Angoulevant, Azeline Chevance, Lawrence Serfaty, Teresa Antonini, Audrey Coilly, Jean-Charles Duclos Vallée, Mariagrazia Tateo, Corinne Bonny, Chanteranne Brigitte, Géraldine Lamblin, Léon Muti, Abdenour Babouri, Virginie Filipe, Abdenour Babouri, Virginie Filipe, Camille Barrault, Laurent Costes, Hervé Hagège, Soraya Merbah, Paul Carrier, Maryline Debette-Gratien, Jérémie Jacques, Guillaume Lassailly, Florent Artu, Valérie Canva, Sébastien Dharancy, Alexandre Louvet, Marianne Latournerie, Marc Bardou, Thomas Mouillot, Yannick Bacq, Didier Barbereau, Charlotte Nicolas, Caroline Chevalier, Isabelle Archambeaud, Sarah Habes, Nisserine Ben Amara, Danièle Botta-Fridlund, Eric Saillard, Marie-Josée Lafrance
- Prior surveillance and antiviral treatment improve the prognosis of HCC developed in HBV patients in the West
- Manon Allaire, Weam El Hajj, Ségolène Brichler, Kadiatou Diallo, Daniela Fanica, Lorraine Blaise, Gisèle Nkontchou, Véronique Grando, Fatima Arbadi, Pierre Nahon, Marianne Ziol, Jean-Charles Nault, Nathalie Ganne-Carrié
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?